Over 1,000,000 women have been screened with TruScreen to date, with a robust safety profile.
Demonstrating a continued commitment to cervical cancer screening solutions.
Our market potential is huge with 1.256 billion women eligible for screening in our key markets (Women 15-64 years - CIA World Factbook)
Globally, an estimated 662,044 cases from cervical cancer occurred in 2022, making it the fourth cause of cancer morbidity and mortality in women worldwide
Our primary screening solution is ideal for communities that cannot access conventional, laboratory dependant, screening methods. It is affordable and easy to learn.
Our purpose is to ensure that all women of screening age, no matter who or where they are, have access to quality screening.
TruScreen is a real-time, objective, AI-enabled screening device. It is CE certified as a primary screening tool. TruScreen screens for the presence of pre-cancerous and cancerous tissue in the cervix.
Real-time Results
Immediate feedback to patient and operator. Patient can be treated if necessary at time of visit. Patient not lost to follow-up with delayed reporting.
Objective result
Accurate result every time. Reproducible, consistent results to confirm accuracy.
No lab facility needed
Greater access to women in remote communities. Easy to use. No qualified cytologists needed. Suitable for remote areas and developing countries. Cost savings in resources / overheads.
High sensitivity
Assured level of performance. High standard of cervical screening. Improved ability to detect disease and save lives. Economic savings to global healthcare systems.
Cervical cancer is one of the most common cancers among women, especially in low to middle-income countries where screening rates are low.
With effective screening and early detection, cervical cancer is highly preventable. Technologies like TruScreen can significantly reduce incidence and mortality rates.
Early detection and treatment are far less expensive than treating advanced cancer, making it a cost-effective investment for healthcare systems.
Improving women’s health has a ripple effect on families and communities, enhancing overall societal well-being.
There’s a growing demand for innovative, accessible, and affordable healthcare solutions in emerging markets.
TruScreen Group Ltd manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and process designed to detect the presence in real time of pre-cancerous and cancerous tissue on the cervix.
